Not yet recruiting NCT07367932
Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Application of crisaborole twice daily, Tacrolimus ointment in atopic dermatitis.
- Who it may be relevant to
- Registry conditions: Dermatitis, Atopic, Eczema. Basic parameters: 5 years — 25 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Crisaborole 2% Versus Tacrolimus 0.03% Ointments for the Treatment of Mild to Moderate Atopic Dermatitis: A Comparative Study
Overview
This study will compare the efficacy and safety of crisaborole ointment with tacrolimus ointment, in the treatment of patients with mild-to-moderate atopic dermatitis.
Interventions
- Drug Application of crisaborole twice daily
compare the efficacy and safety of crisaborole ointment on mild to moderate atopic dermatitis for 1 month and followup in 2 months - Drug Tacrolimus ointment in atopic dermatitis
compare the efficacy and safety of tacrolimus ointment, in the treatment of patients with mild-to-moderate atopic dermatitis
Primary outcome measures
- Improvement of Investigator's Static Global Assessment score [Time frame: 3 months]
- Improvement of Eczema Area and Severity Index [Time frame: 3 months]
Eligibility criteria
Inclusion criteria
- Patients with diagnosis of AD, according to Hanifin and Rajka criteria.
- Patients of both genders
- Age 5-25 years
- Baseline Investigator's Static Global Assessment (ISGA) score of mild (2) or moderate (3).
Exclusion criteria
- Clinically infected eczema.
- Baseline Investigator's Static Global Assessment (ISGA) score of severe (4).
- Associated comorbidities that exacerbate pruritus.
- Patients receiving topical treatment for AD and/or pruritus within the past 14 days and/or systemic treatment within the past month.
- Pregnancy and lactation if in the childbearing period
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07367932 · MS-61-2025